Apimeds Pharmaceuticals US
APUS
6 hedge funds and large institutions have $803K invested in Apimeds Pharmaceuticals US in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.
24% more capital invested
Capital invested by funds: $649K → $803K (+$154K)
0.04% more ownership
Funds ownership: 0.31% → 0.36% (+0.04%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
14% less funds holding
Funds holding: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$17K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.31K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$44.6K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$66 |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$16 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HTHT
1
Hemenway Trust Hemenway Trust
Salem,
New Hampshire
| $490K | – | – | – |
|
|
VCM
2
Vanguard Capital Management
Malvern,
Pennsylvania
| $172K | +$154K | +9,593 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $71.7K | +$8.31K | +516 | +15% |
|
|
VFT
4
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $43K | +$38.7K | +2,404 | New |
|
|
TSS
5
Two Sigma Securities
New York
| $18.9K | +$17K | +1,055 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $7.49K | +$5.81K | +361 | +622% |
|
|
7
Jane Street
New York
| – | -$44.6K | -2,719 | Closed |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$66 | -4 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$16 | -1 | Closed |
|
APUS Hedge Fund Activity: Q1 2026 in Review
6 of the 8,161 institutional investors tracked by Wall St. Rank reported a position in Apimeds Pharmaceuticals US (APUS) for Q1 2026, worth a combined $803K — up 24% from $649K a quarter earlier.
Fund positioning in APUS was balanced in Q1 2026: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $17K. The largest seller was Jane Street, exiting entirely with an estimated $44.6K sold.
- 6 institutional investors held Apimeds Pharmaceuticals US (APUS) as of Q1 2026, down from 7 in Q4 2025.
- Funds reported $803K of Apimeds Pharmaceuticals US stock for Q1 2026, up 24% quarter-over-quarter.
- 3 funds opened new Apimeds Pharmaceuticals US positions in Q1 2026 and 3 closed out, a net change of 0 holders.
- The largest Apimeds Pharmaceuticals US buyer in Q1 2026 was Two Sigma Securities, an estimated $17K added.
- The largest Apimeds Pharmaceuticals US seller in Q1 2026 was Jane Street, an estimated $44.6K sold.
Based on aggregated 13F filings for Q1 2026.